JAK1 somatic mutation in a myeloproliferative neoplasm

Suzanne O. Arulogun, Hock-Lai Choong, Debbie Taylor, Paula Ambrosoli, Graham Magor, Ian M. Irving, Tee-Beng Keng, and Andrew C. Perkins

Disclosures: ACP received funding for speaking engagements from Novartis Oncology and CTI Pty Ltd.

Contributions: SOA collated the clinical data, prepared Figure 1 and co-wrote the manuscript; ACP developed and supervised the NGS platform and co-wrote the manuscript; H-LC was an attending clinician; DT supervised the clinical application of the NGS platform; PA undertook the NGS run, GM undertook bioinformatics analyse and prepared Figure 2; T-BK supervised the haemato-pathology reporting; IWI was an attending clinician.